GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GlaxoSmithKline plc (GSK) CEO Emma Walmsley on Q3 2019 Results - Earnings Call Transcript

Glaxo beats both earnings and sales estimates in the third quarter of 2019.

Glaxo (GSK) Beats Earnings & Revenue Estimates in Q3

Johnson & Johnson

Which stock is the better pick between these two healthcare giants?

Better Buy: Johnson & Johnson vs. GlaxoSmithKline

Incyte

Jazz Pharmaceuticals

Vertex Pharmaceuticals

Zoetis

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the third quarter.

5 Drug/Biotech Stocks Likely to Surpass on Earnings in Q3

GlaxoSmithKline said U.S. regulators had approved its ovarian cancer treatment Zejula for wider use in some advanced cancers.

GlaxoSmithKline gets regulatory nod for wider use of ovarian cancer drug Zejula

Amgen

Comcast

Microsoft

AT&T

Despite almost day-to-day market fluctuations, a few corporate behemoths surged in Wall Street. Some of these are set to beat earnings estimate in the ongoing reporting cycle.

5 High-Flying Corporate Giants Set to Beat on Q3 Earnings

Merck

Which pharmaceutical stock could provide investors with the best possible return?

Better Buy: GlaxoSmithKline vs. Merck

Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer significantly reduces risk of disease progression or death by 38%.

Glaxo's Zejula Betters PFS in First-Line Ovarian Cancer Study

AstraZeneca

GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients.

Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use

Is the debt-laden British pharmaceutical giant a good investment now?

Is GlaxoSmithKline a Buy?

Eli Lilly

Novo Nordisk

Pfizer

How Big Can This $8 Billion-Plus Diabetes Drug Class Get?

GlaxoSmithKline achieved positive results from its phase 3 ATLAS-2M study using injectable cabotegravir and rilpivirine to treat patients with HIV.

GlaxoSmithKline Makes A Bold Statement With Latest HIV Data

Glaxo's (GSK) SLE drug Benlysta gets a favorable CHMP opinion that recommends an approval for intravenous formulation in pediatric patients.

Glaxo's Benlysta Gets Positive CHMP Opinion for Use in Kids

SYDNEY, Australia, Sept.  23, 2019  (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces that it will receive a milestone payment from GSK of £4 million (~US$5.02 million) related to the first patient being dosed in GSK’s Phase II clinical trial evaluating GSK2831781 in ulcerative colitis.

Immutep to Receive £4M Milestone Payment From GSK

Glaxo's (GSK) asthma medicine, Nucala gets FDA approval for use in pediatric patient population.

Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use

Alibaba

NetEase

3 International Stocks Worth Watching

Shares of Glaxo (GSK) surpass the industry this year. Here are some reasons for the same.

Here's Why Glaxo (GSK) Steadily Stays Ahead of Its Industry

Glaxo (GSK) seeks approval for its anemia candidate, daprodustat, in Japan. Moreover, once every two months administration of cabotegravir and rilpivirine shows non-inferiority to once a month administration in HIV patients in a clinical study.

Glaxo Submits First Regulatory Application for Daprodustat

Which stock wins in this big pharma matchup?

Better Buy: Eli Lilly vs GlaxoSmithKline

Let's see if GlaxoSmithKline (GSK) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Consider GlaxoSmithKline (GSK) Stock?

GlaxoSmithKline achieved the primary endpoint for its phase 3 study using Zejula as first-line maintenance therapy for ovarian cancer patients.

GlaxoSmithKline Advances Forward With Zejula In Another Indication For Increased Sales

GlaxoSmithKline Looks To Boost Sales Of Zejula Upon Potential FDA Approval In Another Indication

Thermo Fisher Scientific

It looks like 2019's going to be much better than expected for these giants operating in different corners of the healthcare sector.

Three Healthcare Stocks With Rising Expectations.

Glaxo (GSK) beats on earnings and sales in the second quarter. Strong growth of vaccine and respiratory portfolio boosts sales.

Glaxo (GSK) Beats on Q2 Earnings, Shingrix Sales Strong

GlaxoSmithKline PLC (GSK) CEO Emma Walmsley on Q2 2019 Results - Earnings Call Transcript

News for GlaxoSmithKline Stock (GSK)